What are the key financial highlights for FY26?

Concord Drugs reported standalone revenue of ₹75.85 crore, more than double the ₹36.93 crore recorded in FY25. Net profit for the period rose to ₹1.04 crore from ₹0.30 crore.

Are these results new to the market?

No. The company previously disseminated these financial results in an earlier filing.

Did the auditor raise any specific concerns?

The auditor included an emphasis of matter regarding ₹4.14 crore in long-overdue trade receivables. This issue is not new.

Earnings · Pharmaceuticals · Micro cap

Concord Drugs reports FY26 revenue growth to ₹75.85 crore

Standalone revenue doubled in FY26, though the market already received these figures in a prior filing.

— 1 earlier story on Concord Drugs Ltd. →

CONCORD 27 May 2026 · 4:37 PM IST Verify on BSE · NSE

Mkt cap₹109 cr

P/E192.97×

ROE0.99%

Debt / eq.0.56

₹75.85 cr Standalone revenue for FY26, up from ₹36.93 crore in FY25.

What's new

Board approved audited standalone and consolidated results for Q4 and FY26.
Standalone revenue rose to ₹75.85 crore from ₹36.93 crore.
Net profit increased to ₹1.04 crore from ₹0.30 crore.

Why this matters

The growth is material for a nano-cap company. However, the lack of new information limits the impact of this filing. Investors should focus on the auditor's concern regarding long-overdue receivables.

What we're watching

Progress on the recovery of ₹4.14 crore in overdue trade receivables.
Management commentary on sustaining revenue growth in FY27.
Any further auditor qualifications in upcoming quarterly reports.

The full read

Concord Drugs has formally approved its audited standalone and consolidated financial results for FY26. The company reported a sharp increase in standalone revenue to ₹75.85 crore, up from ₹36.93 crore in the prior year. Net profit also climbed to ₹1.04 crore from ₹0.30 crore.

It is routine.

Despite these gains, the filing provides no fresh information because the figures were already disclosed to the market in a prior release. The auditor continues to flag ₹4.14 crore in long-overdue trade receivables, which remains a recurring concern for the company. For a nano-cap entity, the scale of growth is visible, but the lack of new developments makes this a procedural filing that adds nothing to the existing investment thesis.

Questions answered

What are the key financial highlights for FY26?: Concord Drugs reported standalone revenue of ₹75.85 crore, more than double the ₹36.93 crore recorded in FY25. Net profit for the period rose to ₹1.04 crore from ₹0.30 crore.
Are these results new to the market?: No. The company previously disseminated these financial results in an earlier filing.
Did the auditor raise any specific concerns?: The auditor included an emphasis of matter regarding ₹4.14 crore in long-overdue trade receivables. This issue is not new.

Mentioned: Concord Drugs Ltd · ₹75.85 cr revenue · ₹4.14 cr receivables

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on CONCORD →

27 May 2026 · 4:37 PM IST Concord Drugs reports FY26 revenue growth to ₹75.85 crore
today Concord Drugs doubles revenue to ₹75.85 cr, but auditor flags receivables